Duration from start of antibiotic exposure to onset of Clostridioides difficile infection for different antibiotics in a non-outbreak setting

References

• Brown K, Valenta K, Fisman D, et al. Hospital ward antibiotic prescribing and the risks of Clostridium difficile infection. JAMA Intern Med. 2015;175(4):626–633. doi: 10.1001/jamainternmed.2014.8273.
   PubMed Web of Science ®Google Scholar
• Webb BJ, Subramanian A, Lopansri B, et al. Antibiotic exposure and risk for hospital-associated clostridioides difficile infection. Antimicrob Agents Chemother. 2020;64(4):e02169-19. doi: 10.1128/AAC.02169-19.
   Web of Science ®Google Scholar
• Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2014;69(4):881–891. doi: 10.1093/jac/dkt477.
   PubMed Web of Science ®Google Scholar
• Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372(16):1539–1548. doi: 10.1056/NEJMra1403772.
   PubMed Web of Science ®Google Scholar
• Fu Y, Luo Y, Grinspan AM. Epidemiology of community-acquired and recurrent Clostridioides difficile infection. Therap Adv Gastroenterol. 2021;14:17562848211016248. doi: 10.1177/17562848211016248.
   Web of Science ®Google Scholar
• Heimann SM, Cruz Aguilar MR, Mellinghof S, et al. Economic burden and cost-effective management of Clostridium difficile infections. Med Mal Infect. 2018;48(1):23–29. doi: 10.1016/j.medmal.2017.10.010.
   PubMed Web of Science ®Google Scholar
• Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–834. doi: 10.1056/NEJMoa1408913.
   PubMed Web of Science ®Google Scholar
• Walker AS, Eyre DW, Wyllie DH, et al. Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis. 2013;56(11):1589–1600. doi: 10.1093/cid/cit127.
   PubMed Web of Science ®Google Scholar
• Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect. 1998;40(1):1–15. doi: 10.1016/s0195-6701(98)90019-6.
   PubMed Web of Science ®Google Scholar
• Mehta P, Nahass RG, Brunetti L. Acid suppression medications during hospitalization as a risk factor for recurrence of Clostridioides difficile infection: systematic review and meta-analysis. Clinical Infect Dis. 2020;73(1):e62–e68. doi: 10.1093/cid/ciaa545.
   Web of Science ®Google Scholar
• Vaishnavi C. Established and potential risk factors for Clostridum difficile infection. Indian J Med Microbiol. 2009;27(4):289–300. doi: 10.4103/0255-0857.55436.
   PubMed Web of Science ®Google Scholar
• Hebbard AIT, Slavin MA, Reed C, et al. The epidemiology of Clostridium difficile infection in patients with cancer. Expert Rev Anti Infect Ther. 2016;14(11):1077–1085. doi: 10.1080/14787210.2016.1234376.
   PubMed Web of Science ®Google Scholar
• Stevens V, Dumyati G, Fine LS, et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011;53(1):42–48. doi: 10.1093/cid/cir301.
   PubMed Web of Science ®Google Scholar
• Karp J, Edman-Waller J, Toepfer M, et al. Clostridioides difficile incidence related to in-hospital cephalosporin use: a tale of two highly comparable hospitals. J Antimicrob Chemother. 2019;74(1):182–189. doi: 10.1093/jac/dky408.
   PubMed Web of Science ®Google Scholar
• Hensgens MP, Goorhuis A, Dekkers OM, et al. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012;67(3):742–748. doi: 10.1093/jac/dkr508.
   PubMed Web of Science ®Google Scholar
• Thabit AK, Varugehese CA, Levine AR. Antibiotic use and duration in association with Clostridioides difficile infection in a tertiary academic medical center: a retrospective case-control study. Anaerobe. 2019;59:126–130. doi: 10.1016/j.anaerobe.2019.06.016.
   PubMed Web of Science ®Google Scholar
• Rizzardi K, Norén T, Aspevall O, et al. National surveillance for Clostridioides difficile Infection, Sweden, 2009–2016. Emerg Infect Dis. 2018;24(9):1617–1625. doi: 10.3201/eid2409.171658.
   PubMed Web of Science ®Google Scholar
• Mcdonald LC, Coignard B, Dubberke E, et al. Recommendations for Surveillance of Clostridium difficile-associated Disease. Infect Control Hosp Epidemiol. 2007;28(2):140–145. doi: 10.1086/511798.
   Google Scholar
• Norén T. Clostridioides difficile infection, guidelines on behalf of Swedish society of phisicians in infectious diseases https://infektion.net/wp-content/uploads/2017/05/vardprogram_cdi_infektionslakarforeningen_slutversion.pdf.
   Google Scholar
• Privitera G, Scarpellini P, Ortisi G, et al. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother. 1991;35(1):208–210. doi: 10.1128/AAC.35.1.208.
   PubMed Web of Science ®Google Scholar
• Dubberke ER, Reske KA, Seiler S, et al. Risk factors for acquisition and loss of Clostridium difficile colonization in hospitalized patients. Antimicrob Agents Chemother. 2015;59(8):4533–4543. doi: 10.1128/AAC.00642-15.
   PubMed Web of Science ®Google Scholar
• Anjewierden S, Han Z, Brown AM, et al. Risk factors for Clostridioides difficile colonization among hospitalized adults: a meta-analysis and systematic review. Infect Control Hosp Epidemiol. 2021;42(5):565–572. doi: 10.1017/ice.2020.1236.
   PubMed Web of Science ®Google Scholar
• Branch-Elliman W, O'Brien W, Strymish J, et al. Association of duration and type of surgical prophylaxis with antimicrobial-associated adverse events. JAMA Surg. 2019;154(7):590–598. doi: 10.1001/jamasurg.2019.0569.
   PubMed Web of Science ®Google Scholar
• Patel N, Gorseth A, Belfiore G, et al. Fluoroquinolone-associated adverse events of interest among hospitalized veterans affairs patients with community-acquired pneumonia who were treated with a fluoroquinolone: a focus on tendonitis, Clostridioides difficile infection, and aortic aneurysm. Pharmacotherapy. 2023;44(1):49–60. doi: 10.1002/phar.2877.
   PubMed Web of Science ®Google Scholar
• Sholeh M, Krutova M, Forouzesh M, et al. Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2020;9(1):158. doi: 10.1186/s13756-020-00815-5.
   PubMed Web of Science ®Google Scholar
• Razavi B, Apisarnthanarak A, Mundy LM. Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection. 2007;35(5):300–307. doi: 10.1007/s15010-007-6113-0.
   PubMed Web of Science ®Google Scholar
• Davies K, Lawrence J, Berry C, et al. Risk factors for primary clostridium difficile infection; results from the observational study of risk factors for Clostridium difficile Infection in hospitalized patients with infective diarrhea (ORCHID). Front Public Health. 2020;8:293. doi: 10.3389/fpubh.2020.00293.
   PubMed Web of Science ®Google Scholar